Catalent (CTLT) Earnings Date and Reports 2025 - MarketBeat

Dec 18, 2024 · Catalent has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, February 14th, 2025 based off last year's report dates. …

CouponFollow Extension

4%
OFF

Catalent Inc. Reports Q1 Fiscal 2025 Results - Nasdaq

2 weeks from now

Nov 6, 2024 · For the first quarter of fiscal 2025, Catalent Inc. reported a net revenue increase of 4% to $1.02 billion compared to the same period last year. Excluding COVID-related …

nasdaq.com

2%
OFF

Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?

2 weeks from now

Dec 5, 2024 · A month has gone by since the last earnings report for Catalent (CTLT). Shares have added about 3.2% in that time frame, outperforming the S&P 500. ... Catalent exited first …

nasdaq.com

2%
OFF

Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?

2 weeks from now

Dec 5, 2024 · A month has gone by since the last earnings report for Catalent (CTLT). Shares have added about 3.2% in that time frame, outperforming the S&P 500. ... Catalent reported …

yahoo.com

$63.48
OFF

Catalent (NYSE:CTLT) Now Covered By Analysts At StockNews.com

2 weeks from now

Jan 12, 2025 · NYSE CTLT opened at $63.48 on Friday. Catalent has a 1-year low of $41.15 and a 1-year high of $63.50. The company has a market capitalization of $11.52 billion, a P/E ratio …

etfdailynews.com

11%
OFF

Catalent Reports Q1 EPS (13c), Consensus 5c - Nasdaq

2 weeks from now

Nov 5, 2024 · Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1’24. …

nasdaq.com

$63.48
OFF

Catalent (NYSE:CTLT) Earns Hold Rating From Analysts ... - ETF …

2 weeks from now

Jan 28, 2025 · Shares of NYSE CTLT opened at $63.48 on Tuesday. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. Catalent has a 52 week …

etfdailynews.com

FAQs about Catalent (CTLT) Earnings Date and Reports 2025 - MarketBeat Coupon?

Did Catalent beat analysts' estimates for fourth-quarter revenue?

Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies. Get the latest Catalent, Inc. (CTLT) stock price quote with news, financials and other important investing information. ...

Is Catalent a good stock to buy?

Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Eight investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $63.40. ...

What were Catalent's Financial Highlights in the quarter?

Financial highlights in the quarter included double-digit year-over-year growth in both non-COVID revenue and adjusted EBITDA, while also delivering positive free cash flow," said Alessandro Maselli, President and Chief Executive Officer of Catalent, Inc. ...

How have large investors changed their holdings of Catalent?

A number of large investors have recently modified their holdings of the business. Brooklyn Investment Group acquired a new position in shares of Catalent in the 3rd quarter worth approximately $31,000. Blue Trust Inc. boosted its holdings in shares of Catalent by 88.7% in the fourth quarter. ...

How do I receive news & ratings for Catalent?

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter. ...

Does sentry investment management own Catalent?

Sentry Investment Management LLC acquired a new position in shares of Catalent in the third quarter worth about $53,000. Thurston Springer Miller Herd & Titak Inc. boosted its holdings in shares of Catalent by 57.5% in the third quarter. ...